MGH Institute of Health Professions
Boston, Massachusetts, 02129, United States
Location status: Recruiting
Location contact
Karen Chenausky, PhD
CONTACT
Karen V Chenausky, PhD
PRINCIPAL_INVESTIGATOR
Steve Meyer
CONTACT
NCT Number: NCT05066178
Comorbid Childhood Apraxia of Speech (CAS) may be one factor that limits speech development in some minimally verbal children with autism. CAS is a disorder affecting speech movement planning. This study tests whether CAS-specific treatment, appropriately modified for minimally verbal children with autism, improves their speech.
Interested in participating?
Request Info5 year–18 year
All sexes
Interventional
Not applicable
Boston, Massachusetts, 02129, United States
Location status: Recruiting
Karen Chenausky, PhD
CONTACT
Karen V Chenausky, PhD
PRINCIPAL_INVESTIGATOR
Steve Meyer
CONTACT
Although one in four children with autism remain minimally verbal past age five, not all the factors that limit spoken language in these minimally verbal children are known. One powerful contributor may be a motor speech disorder, Childhood Apraxia of Speech (CAS). CAS is an impairment in the ability to plan and sequence for speech, which makes speech inconsistent and imprecise. This project proposes to investigate whether CAS makes the speech of minimally verbal children with autism unintelligible, and then to test whether treating the CAS improves children's speech.
First, a cohort of 20 minimally verbal children with both autism and CAS is identified. The prediction is that the more severe the CAS, the more inconsistent and imprecise a child's speech, and therefore the lower their intelligibility will be. Then, a set of mono- and bisyllabic words is selected that contain the disordered movements that each child shows and use those in treatment.
Treatment will take the form of 15 one-hour sessions where speech practice is embedded in a naturalistic, play-based milieu that is centered on each child's own developmental level. It will involve principles of motor learning (intensive practice of a few words, sometimes all in a row and sometimes mixed up). Different types of cues (touch cues, simultaneous production, etc.) will also be employed to help children say their words correctly, fading back these supports as the child's speech improves. Both of these techniques have been shown to be effective for treating CAS.
Our outcome measures will include both (1) "by-ear" assessments of intelligibility and (2) acoustic and kinematic measurements of children's speech after 15 treatment sessions. The findings will inform clinical practice for minimally verbal children with autism and may lead to the development of novel interventions for this severely affected population.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Treatment involves principles of motor learning embedded in a naturalistic developmental milieu
Time frame: 5 weeks
Number or percent of target items that were produced correctly
Time frame: 5 weeks
Number or percent of phonemes (vowels, consonants) in the target items that were produced correctly
Time frame: 5 weeks
Amount of variability in lip opening area during production of multiple attempts at the same target
Time frame: 5 weeks
Acoustic distinctiveness of different phonemes
Contact information is provided by the study sponsor or research team.
Karen V Chenausky, Ph.D.
CONTACT
Michael Moody
CONTACT
MGH Institute of Health Professions
Other
Acronym: TxMVASD+CAS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04764539
Apraxia of Speech, Apraxias
Vallejo, California, United States
View Trial DetailsNCT06081348
22Q11 Deletion, 22q11 Deletion Syndrome
Calgary, Alberta, Canada
View Trial DetailsNCT06726187
Autism Spectrum Disorder, Autistic Disorder
Rotterdam, Netherlands
View Trial DetailsNCT03866668
Autism, Autism Spectrum Disorder
Stanford, California, United States
View Trial Details